| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
SGLT2 inhibition--a novel strategy for diabetes treatment.
|
Nat Rev Drug Discov
|
2010
|
4.22
|
|
2
|
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
|
N Engl J Med
|
2017
|
4.18
|
|
3
|
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future.
|
Lancet
|
2013
|
2.66
|
|
4
|
Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.
|
Am Heart J
|
2013
|
2.12
|
|
5
|
SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.
|
Diab Vasc Dis Res
|
2015
|
1.73
|
|
6
|
Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes.
|
Diabetes Care
|
2014
|
1.52
|
|
7
|
The kidney in type 2 diabetes therapy.
|
Rev Diabet Stud
|
2011
|
1.50
|
|
8
|
Update on developments with SGLT2 inhibitors in the management of type 2 diabetes.
|
Drug Des Devel Ther
|
2014
|
1.14
|
|
9
|
A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor.
|
Diabetes Metab J
|
2014
|
1.14
|
|
10
|
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™).
|
Cardiovasc Diabetol
|
2014
|
1.12
|
|
11
|
Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus.
|
Diabetes Metab Syndr Obes
|
2014
|
1.05
|
|
12
|
Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus.
|
J Clin Endocrinol Metab
|
2015
|
1.03
|
|
13
|
Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies.
|
Curr Med Res Opin
|
2014
|
1.03
|
|
14
|
Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR).
|
Curr Med Res Opin
|
2014
|
1.01
|
|
15
|
SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
|
Diabetologia
|
2016
|
0.98
|
|
16
|
Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus.
|
Cardiovasc Diabetol
|
2015
|
0.98
|
|
17
|
Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus.
|
Diabetes Ther
|
2013
|
0.98
|
|
18
|
Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin.
|
Nutr Diabetes
|
2014
|
0.91
|
|
19
|
Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial.
|
Diabetes Ther
|
2015
|
0.86
|
|
20
|
Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus.
|
Clin Med Insights Endocrinol Diabetes
|
2015
|
0.85
|
|
21
|
The efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitus.
|
Curr Med Res Opin
|
2015
|
0.85
|
|
22
|
Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations.
|
Circulation
|
2016
|
0.84
|
|
23
|
Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents.
|
Drugs Context
|
2014
|
0.79
|
|
24
|
Current perspectives on cardiovascular outcome trials in diabetes.
|
Cardiovasc Diabetol
|
2016
|
0.79
|
|
25
|
Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus.
|
N Am J Med Sci
|
2014
|
0.78
|
|
26
|
Novel drugs and intervention strategies for the treatment of chronic kidney disease.
|
Br J Clin Pharmacol
|
2013
|
0.78
|
|
27
|
Simultaneous Reduction in Both HbA1c and Body Weight with Canagliflozin Versus Glimepiride in Patients with Type 2 Diabetes on Metformin.
|
Diabetes Ther
|
2016
|
0.78
|
|
28
|
Canagliflozin-current status in the treatment of type 2 diabetes mellitus with focus on clinical trial data.
|
World J Diabetes
|
2014
|
0.76
|
|
29
|
Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
|
Vasc Health Risk Manag
|
2016
|
0.75
|
|
30
|
Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program.
|
Diabetologia
|
2019
|
0.75
|
|
31
|
Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin.
|
J Am Coll Cardiol
|
2022
|
0.75
|
|
32
|
Cardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic Medications.
|
Clin Pharmacol Ther
|
2015
|
0.75
|
|
33
|
Effects of Baseline Blood Pressure and Low-Density Lipoprotein Cholesterol on Safety and Efficacy of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus.
|
Adv Ther
|
2015
|
0.75
|
|
34
|
Glucose-lowering therapy in type 2 diabetes. New hope after the EMPA-REG outcome trial.
|
Herz
|
2016
|
0.75
|
|
35
|
Cardiovascular effects of anti-diabetes drugs.
|
Expert Opin Drug Saf
|
2016
|
0.75
|
|
36
|
Diabetes Drugs and Cardiovascular Safety.
|
Endocrinol Metab (Seoul)
|
2016
|
0.75
|
|
37
|
Blood pressure and cardiovascular effects of new and emerging antidiabetic agents.
|
Curr Hypertens Rep
|
2014
|
0.75
|
|
38
|
Closing the knowledge gap on cardiovascular disease in type 2 diabetes: the EMPA-REG OUTCOME trial and beyond.
|
Drugs Context
|
2016
|
0.75
|
|
39
|
Canagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 Diabetes.
|
Diabetes Ther
|
2016
|
0.75
|